Actuate Therapeutics’ (NASDAQ:ACTU) Quiet Period To End on September 23rd

Actuate Therapeutics’ (NASDAQ:ACTU) quiet period is set to end on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During Actuate Therapeutics’ quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Actuate Therapeutics Stock Up 2.4 %

ACTU stock opened at $8.19 on Friday. The stock has a market cap of $156.51 million and a price-to-earnings ratio of 54.60. Actuate Therapeutics has a twelve month low of $7.33 and a twelve month high of $10.16.

Insiders Place Their Bets

In related news, Director Equity Cof Lp Bios bought 500,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were acquired at an average cost of $8.00 per share, with a total value of $4,000,000.00. Following the completion of the purchase, the director now directly owns 1,259,427 shares of the company’s stock, valued at approximately $10,075,416. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Equity Cof Lp Bios acquired 500,000 shares of Actuate Therapeutics stock in a transaction dated Wednesday, August 14th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $4,000,000.00. Following the transaction, the director now owns 1,259,427 shares of the company’s stock, valued at $10,075,416. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Leslie W. Kreis sold 24,999 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total value of $224,991.00. Following the completion of the sale, the insider now owns 131,248 shares of the company’s stock, valued at approximately $1,181,232. The disclosure for this sale can be found here. Corporate insiders own 19.90% of the company’s stock.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.